About DURECT
DURECT is a company based in Cupertino (United States) founded in 1998 by James E. Brown was acquired by Bausch Health in July 2025. The company has 79 employees as of December 31, 2022. DURECT operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Cupertino, United States
- Employees 79 as on 31 Dec, 2022
- Founders James E. Brown
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Durect Corporation
-
Annual Revenue
$189 K (USD)-93as on Dec 31, 2024
-
Net Profit
-$8.32 M (USD)70as on Dec 31, 2024
-
EBITDA
-$18.91 M (USD)52as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
79
as on Dec 31, 2022
-
Acquired by
Bausch Health
(Jul 29, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of DURECT
DURECT is a publicly listed company on the NASDAQ with ticker symbol DRRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of DURECT
Unlock access to complete
Unlock access to complete
Funding Insights of DURECT
Detailed funding history for DURECT
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in DURECT
DURECT has secured backing from 1 investor. Prominent investors backing the company include Bausch Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
Locked | Locked | Locked |
Investor details for DURECT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DURECT
Investment portfolio details for DURECT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DURECT
Detailed financials for DURECT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Durect Comparisons
Peer comparison for DURECT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DURECT
DURECT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of DURECT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Durect
Complete news archive for DURECT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DURECT
DURECT was founded in 1998.
DURECT is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
James E. Brown is the current CEO of DURECT. They have also founded this company.
As of Dec 31, 2022, the latest employee count at DURECT is 79.
Annual revenue of DURECT is $189K as on Dec 31, 2024.
Developer of therapeutics for chronic diseases and pain. Commercial products include alzet osmotic pumps and absorbable polymers. It has various drug delivery platforms like a cloud, oradur, and transducer. It utilizes these technologies for its pipeline candidates which include DUR-928or chronic liver disease, posimir in the new drug application stage (NDA) for post-operative pain, remoxy in the NDA stage for chronic pain,.
DURECT's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Yes, DURECT is publicly traded on NASDAQ under the ticker symbol DRRX.
DURECT has 1 investor. Key investors include Bausch Health.
The ticker symbol of DURECT is DRRX on NASDAQ.